Live news related to UCB stock (BE0003739530): press releases, earnings publications, share price moves, analyst notes and corporate events. This page is auto-updated whenever new financial information is available.
The latest financial news on UCB mainly cover M&A activity, analyst notes et guidance and outlook. The stock trades at €281,40 on Euronext Paris, up 0,50% at the last update. This page lists the articles published on UCB stock to track the share price, company announcements and any item likely to influence market perception.
The Belgian pharmaceutical company is enjoying one of the strongest trading sessions in its recent history. The stock is reacting to the upward revisi…
The Belgian laboratory now anticipates adjusted EBITDA growth approximately twice as fast as revenue growth. This upgrade is based on both volume incr…
The Belgian pharmaceutical company announced, in a press release published on October 16, 2026, that the U.S. health authority has approved a self-inj…
Belgian pharmaceutical company UCB presented a series of data on its drug Bimzelx (bimekizumab) at the Congress of the European Academy of Dermatology…
Belgian pharmaceutical company UCB announced, in a press release published on September 29, 2026, the presentation of a series of data from its portfo…
The Belgian pharmaceutical company obtained from the American drug agency a status designed to accelerate the development of Cimzia to prevent pregnan…
Belgian pharmaceutical company UCB detailed, in a press release published on September 1, 2026, its participation in the 16th European Congress of Epi…
UCB announced on August 31, 2026, that it has concluded an agreement with the United States government concerning access to medicines and investment i…
UCB presented new clinical data at the International Congress on Neuromuscular Diseases (ICNMD) 2026, demonstrating that rozanolixizumab administered …
UCB: Two studies confirm the efficacy of Kygevvi in TK2d. The results document improvements in survival and function in treated patients, as well as t…
